
Aignostics Joins Techcyte Fusion® Partner Program to Bring PathoSearch to Fusion AP



BERLIN, GERMANY AND OREM , UT, UNITED STATES, September 12, 2026 /EINPresswire.com/ -- Techcyte, the developer of Fusion, the unified anatomic and clinical pathology AI platform, today announced that Aignostics has joined the Techcyte Fusion® Partner Program. The companies have integrated Aignostics' PathoSearch application into Techcyte Fusion AP, allowing pathologists to search for morphologically similar cases from within the slide viewer, using the image itself rather than a written description.

PathoSearch uses embeddings from Atlas 2, Aignostics' pathology foundation model co-developed with Mayo Clinic, to compare a selected region of an H&E whole slide image with a curated, multi-center reference database of diagnosed cases, annotated and validated by pathologists. At launch, it covers more than 310,000 whole slide images from over 35,000 cases, spanning more than 300 diagnostic entities across 27 organs. For pathologists, this offers a direct way to explore comparable cases when a finding is rare or unfamiliar. For researchers, it offers a way to find cases with similar morphology across a reference set.

From the Fusion AP slide viewer, users select a region of interest within a given image, and Fusion AP captures and passes the image to PathoSearch; no export or upload is needed. Results open in Aignostics' platform, showing similar cases and their associated information. PathoSearch currently supports thoracic, digestive, soft tissue and bone, female genital, and urinary and male genital cancers, with additional malignancies planned over time.

“When a pathologist sees something that doesn't fit, the useful question is 'what else looks like this?' PathoSearch lets them ask it with the image,” said Dr. Tiffany Chen, CMO of Techcyte. “Bringing this into Fusion AP means the reference material is there at the moment it's needed, letting the pathologist focus on the judgment.”

"This integration is an exciting step in our collaboration, because it seamlessly connects the diagnostic workflow with the image based search engine," said Dr. Rosemarie Krupar, VP of

Pathology at Aignostics. "PathoSearch is built on real, diagnosed cases, annotated and validated by pathologists and aligned to the WHO Classification of Tumours. Fusion AP brings that reference material to pathologists right in the viewer they already work in."

PathoSearch is in early access; Fusion AP users can request access through their Techcyte contact.

Techcyte and Aignostics will demonstrate the integration at the 38th European Congress of Pathology, taking place September 12–16 in Stockholm. ECP attendees are invited to see the integrated workflow live at booth 539 in Hall B, and learn how PathoSearch connects with Fusion AP.

This initial integration is the first step in the companies' collaboration. Techcyte and Aignostics plan to introduce additional integrations and capabilities within Fusion AP in the coming months.

PathoSearch and Techcyte Fusion AP are for Research Use Only in the United States and are not for diagnostic use.

For more information about the Techcyte Fusion Partner Program, visit techcyte.com/partner-program

###

About Techcyte
Techcyte is transforming the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab.

By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment.

Visit techcyte.com for more information.
Techcyte's anatomic and clinical pathology platform is for Research Use Only in the United States.

About Aignostics
Aignostics is an artificial intelligence company that delivers AI-powered tissue analyses, validated

by pathologists. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine, supporting both biopharma R&D and clinical routine diagnostics. Established in 2020, Aignostics is a spin-off from Charité Berlin, one of the world's largest and most esteemed university hospitals. Aignostics is funded by leading investors such as Mayo Clinic and has operations in Berlin and New York.

More information at: www.aignostics.com
Follow us on LinkedIn: www.linkedin.com/company/aignostics

Troy Bankhead
Techcyte
+1 435-210-6200
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/941567791

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.